A prostate cancer drug developed at UCLA will provide hundreds of millions of dollars for research under a record-setting deal announced Friday by university officials.
Royalty Pharma, a New York-based pharmaceutical investment company, paid $1.14 billion for royalty rights to the drug known as Xtandi. It was the largest-ever technology transfer deal involving a University of California invention.
Image: http://microcapmagazine.com/
